Bavarian Nordic A/S (BVNRY)
USD 9.23
(-0.22%)
USD 9.23
(-0.22%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 15.13 Million DKK | -97.59% |
| 2022 | 629.26 Million DKK | 165.56% |
| 2021 | 236.95 Million DKK | -47.05% |
| 2020 | 447.46 Million DKK | 1.01% |
| 2019 | 442.99 Million DKK | 11.41% |
| 2018 | 397.61 Million DKK | -0.54% |
| 2017 | 399.76 Million DKK | 1245.36% |
| 2016 | 29.71 Million DKK | -5.14% |
| 2015 | 31.32 Million DKK | -5.91% |
| 2014 | 33.29 Million DKK | -53.65% |
| 2013 | 71.83 Million DKK | 94.25% |
| 2012 | 36.98 Million DKK | -58.98% |
| 2011 | 90.15 Million DKK | -7.82% |
| 2010 | 97.8 Million DKK | -4.05% |
| 2009 | 101.92 Million DKK | 0.0% |
| 2008 | - DKK | -100.0% |
| 2007 | 134.67 Million DKK | -9.6% |
| 2006 | 148.97 Million DKK | -28.35% |
| 2005 | 207.91 Million DKK | 46.17% |
| 2004 | 142.24 Million DKK | 0.0% |
| 2003 | - DKK | 0.0% |
| 2002 | - DKK | 0.0% |
| 2001 | - DKK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 86.66 Million DKK | -3.11% |
| 2024 Q2 | 14.18 Million DKK | -3.25% |
| 2023 FY | 15.13 Million DKK | -97.59% |
| 2023 Q3 | 66.54 Million DKK | -92.46% |
| 2023 Q2 | 882.16 Million DKK | 24.71% |
| 2023 Q1 | 707.35 Million DKK | 12.41% |
| 2023 Q4 | 15.13 Million DKK | -77.26% |
| 2022 Q1 | 75.73 Million DKK | -68.04% |
| 2022 FY | 629.26 Million DKK | 165.56% |
| 2022 Q2 | 552.78 Million DKK | 629.9% |
| 2022 Q4 | 629.26 Million DKK | -0.34% |
| 2022 Q3 | 631.42 Million DKK | 14.23% |
| 2021 Q4 | 236.95 Million DKK | 194.09% |
| 2021 FY | 236.95 Million DKK | -47.05% |
| 2021 Q1 | 462.2 Million DKK | 3.29% |
| 2021 Q2 | 457.38 Million DKK | -1.04% |
| 2021 Q3 | 80.57 Million DKK | -82.38% |
| 2020 Q4 | 447.46 Million DKK | -1.46% |
| 2020 Q1 | 469.13 Million DKK | 5.9% |
| 2020 FY | 447.46 Million DKK | 1.01% |
| 2020 Q2 | 466.15 Million DKK | -0.64% |
| 2020 Q3 | 454.08 Million DKK | -2.59% |
| 2019 Q3 | 444.83 Million DKK | -0.81% |
| 2019 FY | 442.99 Million DKK | 11.41% |
| 2019 Q1 | 452.2 Million DKK | 13.73% |
| 2019 Q2 | 448.49 Million DKK | -0.82% |
| 2019 Q4 | 442.99 Million DKK | -0.42% |
| 2018 FY | 397.61 Million DKK | -0.54% |
| 2018 Q4 | 397.61 Million DKK | -0.13% |
| 2018 Q3 | 398.14 Million DKK | -0.13% |
| 2018 Q2 | 398.68 Million DKK | -0.13% |
| 2018 Q1 | 399.22 Million DKK | -0.13% |
| 2017 Q3 | 28.11 Million DKK | -1.86% |
| 2017 Q2 | 28.65 Million DKK | -1.82% |
| 2017 Q1 | 29.18 Million DKK | -1.79% |
| 2017 Q4 | 399.76 Million DKK | 1321.82% |
| 2017 FY | 399.76 Million DKK | 1245.36% |
| 2016 Q2 | 30.29 Million DKK | -1.67% |
| 2016 Q1 | 30.8 Million DKK | -1.64% |
| 2016 FY | 29.71 Million DKK | -5.14% |
| 2016 Q4 | 29.71 Million DKK | -2.19% |
| 2016 Q3 | 30.37 Million DKK | 0.28% |
| 2015 Q1 | 32.8 Million DKK | -1.48% |
| 2015 Q3 | 31.81 Million DKK | -1.5% |
| 2015 Q4 | 31.32 Million DKK | -1.55% |
| 2015 FY | 31.32 Million DKK | -5.91% |
| 2015 Q2 | 32.3 Million DKK | -1.52% |
| 2014 FY | 33.29 Million DKK | -53.65% |
| 2014 Q2 | 67.9 Million DKK | -2.58% |
| 2014 Q1 | 69.7 Million DKK | -2.97% |
| 2014 Q4 | 33.29 Million DKK | -55.73% |
| 2014 Q3 | 75.2 Million DKK | 10.75% |
| 2013 Q4 | 71.83 Million DKK | -3.58% |
| 2013 Q3 | 74.5 Million DKK | -2.23% |
| 2013 Q2 | 76.2 Million DKK | 108.2% |
| 2013 Q1 | 36.6 Million DKK | -1.03% |
| 2013 FY | 71.83 Million DKK | 94.25% |
| 2012 FY | 36.98 Million DKK | -58.98% |
| 2012 Q3 | 83.6 Million DKK | -3.91% |
| 2012 Q2 | 87 Million DKK | 0.69% |
| 2012 Q1 | 86.4 Million DKK | -4.16% |
| 2012 Q4 | 36.98 Million DKK | -55.76% |
| 2011 Q3 | 90.3 Million DKK | 1.35% |
| 2011 Q4 | 90.15 Million DKK | -0.16% |
| 2011 FY | 90.15 Million DKK | -7.82% |
| 2011 Q2 | 89.1 Million DKK | -3.15% |
| 2011 Q1 | 92 Million DKK | -5.93% |
| 2010 Q3 | 98.4 Million DKK | -8.21% |
| 2010 Q4 | 97.8 Million DKK | -0.61% |
| 2010 FY | 97.8 Million DKK | -4.05% |
| 2010 Q1 | 102.8 Million DKK | 0.86% |
| 2010 Q2 | 107.2 Million DKK | 4.28% |
| 2009 Q4 | 101.92 Million DKK | 0.0% |
| 2009 FY | 101.92 Million DKK | 0.0% |
| 2008 FY | - DKK | -100.0% |
| 2007 FY | 134.67 Million DKK | -9.6% |
| 2006 FY | 148.97 Million DKK | -28.35% |
| 2005 FY | 207.91 Million DKK | 46.17% |
| 2004 FY | 142.24 Million DKK | 0.0% |
| 2003 FY | - DKK | 0.0% |
| 2002 FY | - DKK | 0.0% |
| 2001 FY | - DKK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | - USD | -Infinity% |
| SQZ Biotechnologies Company | 20.9 Million USD | 27.615% |
| Evofem Biosciences, Inc. | 8000.00 USD | -189087.5% |
| Santhera Pharmaceuticals Holding AG | 1.75 Million USD | -762.158% |
| Mesoblast Limited | 100.29 Million USD | 84.91% |
| Propanc Biopharma, Inc. | 58.64 Thousand USD | -25709.147% |
| Genus plc | 228.2 Million USD | 93.368% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | - USD | -Infinity% |
| Marizyme, Inc. | 667.12 Thousand USD | -2168.677% |
| ContraFect Corporation | 2.21 Million USD | -584.842% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.4 Million USD | -978.811% |
| Intellipharmaceutics International Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 5.42 Million USD | -178.91% |
| MultiCell Technologies, Inc. | 36.43 USD | -41545329.591% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 55.61 Million USD | 72.785% |
| EV Biologics, Inc. | - USD | -Infinity% |
| Q BioMed Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 2.22 Million USD | -579.919% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -1132.13% |
| Biomind Labs Inc. | - USD | -Infinity% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 166.1 Million USD | 90.888% |
| Oncotelic Therapeutics, Inc. | 1.89 Million USD | -697.222% |
| Skye Bioscience, Inc. | 171.23 Thousand USD | -8738.988% |
| Therapeutic Solutions International, Inc. | 5512.00 USD | -274482.729% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | - USD | -Infinity% |
| IMV Inc. | 27.39 Million USD | 44.76% |
| Acro Biomedical Co., Ltd. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | 322 Thousand USD | -4600.311% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 11.23 Billion USD | 99.865% |
| Halberd Corporation | 150 Thousand USD | -9990.0% |
| Enzolytics Inc. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 300 Thousand USD | -4945.0% |
| Nuo Therapeutics, Inc. | 164.2 Thousand USD | -9117.137% |
| argenx SE | 15.35 Million USD | 1.426% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 20.31 Million USD | 25.487% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 4456.00 USD | -339554.399% |
| Genscript Biotech Corporation | 287.12 Million USD | 94.729% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 126.3 Thousand USD | -11883.183% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -6500.782% |
| American Oriental Bioengineering, Inc. | 554.59 Thousand USD | -2629.043% |
| Provectus Biopharmaceuticals, Inc. | 25.29 Thousand USD | -59724.499% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 8.26 Million USD | -83.144% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 265.63 Thousand USD | -5597.668% |
| ONE Bio Corp. | 592.19 Thousand USD | -2455.733% |
| Reve Technologies, Inc. | 1064.00 USD | -1422362.406% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -10016.032% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -10016.032% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 229.69 Thousand USD | -6489.287% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| CytoDyn Inc. | 141 Thousand USD | -10634.043% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 80 Thousand USD | -18818.75% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -93.543% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 369.04 Thousand USD | -4001.081% |
| International Stem Cell Corporation | 445 Thousand USD | -3301.124% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.15 Million USD | -85.706% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | 457 Thousand USD | -3211.816% |
| Neutra Corp. | - USD | -Infinity% |
| Windtree Therapeutics, Inc. | 1.16 Million USD | -1203.618% |
| PureTech Health plc | 18.25 Million USD | 17.068% |
| Coeptis Therapeutics, Inc. | 150 Thousand USD | -9990.0% |
| IXICO plc | 275 Thousand USD | -5403.636% |
| IntelGenx Technologies Corp. | 11.83 Million USD | -27.84% |
| Gelesis Holdings, Inc. | 26.3 Million USD | 42.472% |
| CSL Limited | 11.23 Billion USD | 99.865% |
| Cellectis S.A. | 36.21 Million USD | 58.203% |